Oxford Nanopore Technologies Plc develops proprietary technology platform for the electronic analysis of single molecules. The firm has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Qui est le CEO de Oxford Nanopore Technologies PLC ?
Dr. Gurdial Sanghera est le Chief Executive Officer de Oxford Nanopore Technologies PLC, il a rejoint l'entreprise depuis 2005.
Quelle est la performance du prix de l'action Oxford Nanopore Technologies PL ?
Le prix actuel de Oxford Nanopore Technologies PL est de $1.73, il a augmenté de 5.79% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Oxford Nanopore Technologies PLC ?
Oxford Nanopore Technologies PLC appartient à l'industrie Life Sciences Tools & Services et le secteur est Health Care
Quel est la capitalisation boursière de Oxford Nanopore Technologies PLC ?
La capitalisation boursière actuelle de Oxford Nanopore Technologies PLC est de $1.6B
Est-ce que Oxford Nanopore Technologies PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour Oxford Nanopore Technologies PLC, y compris 5 achat fort, 11 achat, 3 maintien, 1 vente et 5 vente forte